Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

Key Terms

monoclonal antibody medical

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

semaphorin 3a (sema3a) medical

Semaphorin 3a (sema3a) is a protein that helps guide the growth and movement of nerve cells and blood vessels in the body. Its activity influences how tissues develop and repair themselves. For investors, understanding sema3a is important because changes in its levels can impact health conditions and may influence the development of certain therapies or medical treatments.

alport syndrome medical

Alport syndrome is a genetic condition that affects the kidneys, ears, and eyes, often leading to kidney problems and hearing loss over time. For investors, understanding it is important because health issues linked to genetic diseases can influence the pharmaceutical and healthcare sectors, impacting companies involved in developing treatments or diagnostics for such conditions. It highlights how medical advancements and genetic research can create opportunities or risks in related markets.

randomized, double-blind, placebo-controlled medical

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

fast track designation regulatory

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

orphan drug designation regulatory

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

u.s. food and drug administration (fda) regulatory

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

kidney biopsy medical

A kidney biopsy is a medical procedure that removes a tiny piece of kidney tissue, usually with a needle, so doctors can look under a microscope to diagnose disease or measure how well a treatment is working. For investors, biopsy results can change clinical trial outcomes, regulatory decisions, patient treatment pathways and potential market size for drugs or devices—think of it as taking a close-up snapshot that can confirm or rule out a product’s clinical benefit.

• BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder
• Bayer explores opportunity to address high unmet medical need of patients suffering from AS and advances research efforts through close cooperation with AS patient organizations
• Derived from the strategic research cooperation with Evotec, advancement of BAY 3401016 into ASSESS Phase IIa clinical study is further strengthening Bayer’s development portfolio
• The program has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA)

BERLIN--(BUSINESS WIRE)-- Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigate the efficacy and safety of BAY 3401016 in adult participants with Alport Syndrome.

“The initiation of the ASSESS trial represents an important milestone for our investigational BAY 3401016 program,” said Andrea Haegebarth, Ph.D., Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division. “We are collaborating closely with the patient organization community to gain a deeper understanding of the real challenges faced by people living with Alport Syndrome. We believe BAY 3401016 holds promise as a potential therapeutic approach, and we look forward to assessing its efficacy and safety profile as we advance this important program in our pipeline.”

Alport Syndrome is caused by genetic mutations that affect the type IV collagen found in the kidneys, ears, and eyes. It leads to progressive severe proteinuria, loss of kidney function, and early onset of end-stage renal disease. Diagnosis typically occurs in childhood or adulthood (depending on mutation type) via urine tests, kidney biopsy or genetic testing. Both men and women are affected by Alport Syndrome. Many women may initially have milder symptoms and experience a later onset of disease progression.¹ Currently, there is no specific treatment approved for Alport Syndrome and, despite guideline-recommended therapy, patients still experience progressive decline of kidney function resulting in end-stage kidney disease around their fourth decade of life or even earlier.^2,3 The main goal of the ongoing study is to learn how well BAY 3401016 works in slowing down the loss in kidney function in adults with rapidly progressing AS.

Investigational BAY 3401016 is derived from Bayer’s strategic research collaboration with Evotec. The program has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).

About Alport Syndrome

Alport Syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5) that affect the protein type IV collagen. Type IV collagens are an important component of basement membranes in the kidney, but also other organs, and mutations in these genes result in functional impairment.

People with AS have a high risk of developing chronic kidney disease (CKD), a condition in which there is progressive loss in kidney function over time resulting in end-stage kidney disease. As a consequence, kidneys have lost their ability to remove waste products from the body properly, leading to the need for kidney replacement therapy, which involves either dialysis or a kidney transplant. A common sign of impaired kidney function is the presence of excess of the protein albumin in the urine that is not usually found with healthy kidneys. This condition is known as albuminuria.⁴

About BAY 3401016

The study drug BAY 3401016 is a monoclonal antibody that blocks a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS). By blocking the action of the Sema3A protein, BAY 3401016 may reduce proteinuria and slow down the loss in kidney function due to AS.

About the ASSESS study

The Alport Syndrome Sema3A Efficacy & Safety Study (ASSESS) is a Phase IIa clinical trial with an investigational drug (BAY 3401016) for patients with Alport Syndrome. The main goal of the ASSESS study is to learn more about how well BAY 3401016 works in slowing down the progression of kidney damage in patients with Alport Syndrome with increased albuminuria. The study will also evaluate the safety of the BAY 3401016 and record any side effects experienced by participants. Further details of the trial can be found at www.clinicaltrials.gov (NCT07211685).

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer

aka (2025-0220)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

¹ Chavez E, Goncalves S, Rheault MN, Fornoni A. Alport Syndrome. Adv Kidney Dis Health. 2024 May;31(3):170-179. doi: 10.1053/j.akdh.2024.02.004. PMID: 39004457.

² Torra R, Lipska-Zietkiewicz B, Acke F, Antignac C, Becker JU, Cornec-Le Gall E, van Eerde AM, Feltgen N, Ferrari R, Gale DP, Gear S, Gross O, Haeberle S, Heidet L, Lennon R, Massella L, Pfau K, Pizarro MDPV, Topaloglu R, Wlodkowski T, Zealey H; ERKNet, ERA Genes&Kidney and ESPN Inherited renal disorders working group. Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025 May 30;40(6):1091-1106. doi: 10.1093/ndt/gfae265. PMID: 39673454; PMCID: PMC12209846.

³ Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, Müller GA, Gross O. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 2012 Apr;81(8):779-83. doi: 10.1038/ki.2011.452. Epub 2012 Jan 11. PMID: 22237748.

⁴ Chavez E, Goncalves S, Rheault MN, Fornoni A. Alport Syndrome. Adv Kidney Dis Health. 2024 May;31(3):170-179. doi: 10.1053/j.akdh.2024.02.004. PMID: 39004457.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203769695/en/

Bayer Media Contact:

Anna Kanmaz, phone +49 1741463541

Email: anna.kanmaz@bayer.com

Contact for media inquiries Bayer U.S.:

Elaine Colón, phone +1 732 236 1587

Email: elaine.colon@bayer.com

Source: Bayer